Piramal Pharma Ltd is Rated Sell

Understanding the Current Rating

The current Sell rating for Piramal Pharma Ltd is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. This rating suggests that investors should exercise caution, as the stock exhibits challenges in profitability, financial health, and valuation metrics relative to its peers and historical performance.

Quality Assessment

As of 02 October 2026, Piramal Pharma’s quality grade is assessed as below average. The company has demonstrated weak long-term fundamental strength, with a compounded annual growth rate (CAGR) of operating profits declining at -9.27% over the past five years. This negative growth trend indicates operational challenges and a lack of consistent earnings expansion.

Profitability metrics further underscore this concern. The average Return on Equity (ROE) stands at a mere 0.58%, signalling low profitability generated per unit of shareholders’ funds. Additionally, the company’s ability to service debt is limited, with a high Debt to EBITDA ratio of 6.16 times, reflecting elevated leverage and potential financial risk.

Valuation Considerations

From a valuation perspective, Piramal Pharma is currently considered expensive. The stock trades at an enterprise value to capital employed (EV/CE) ratio of 2.5, which is high relative to its return on capital employed (ROCE) of just 0.7%. This disparity suggests that investors are paying a premium for capital that is not generating commensurate returns.

While the stock is trading at a discount compared to its peers’ average historical valuations, the company’s deteriorating profitability and financial metrics weigh heavily on its valuation appeal. Over the past year, the stock has delivered a modest return of +0.18%, but profits have fallen sharply by -225.1%, highlighting the disconnect between price performance and underlying earnings.

Financial Trend Analysis

The financial trend for Piramal Pharma remains negative as of 02 October 2026. The latest quarterly results for June 2026 reveal a significant decline in profitability, with Profit Before Tax excluding other income (PBT LESS OI) at a loss of ₹96.87 crores, representing a fall of -100.5% compared to the previous four-quarter average.

Return on Capital Employed (ROCE) for the half-year period is at a low 2.61%, while the debt-to-equity ratio has increased to 0.70 times, the highest level recorded recently. These indicators point to weakening operational efficiency and rising financial leverage, which contribute to the cautious stance reflected in the current rating.

Technical Outlook

Technically, the stock exhibits a mildly bullish grade, suggesting some positive momentum in price action despite fundamental weaknesses. Over the last six months, the stock has gained +39.86%, and over three months, it has risen +18.45%. However, short-term price gains have not been supported by improving fundamentals, which tempers enthusiasm for the stock’s near-term prospects.

Recent price movements show a 1-day decline of -3.22% and a 1-week drop of -4.08%, indicating some volatility and potential profit-taking. The year-to-date return stands at +15.87%, but the one-year return is nearly flat at +0.18%, reflecting a challenging environment for sustained gains.

What This Rating Means for Investors

The Sell rating from MarketsMOJO advises investors to approach Piramal Pharma Ltd with caution. The combination of below-average quality, expensive valuation, negative financial trends, and only mildly bullish technicals suggests that the stock may face headwinds in delivering consistent returns going forward.

Investors should carefully weigh the risks associated with the company’s high leverage, declining profitability, and valuation premium before considering exposure. The current rating implies that better opportunities may exist elsewhere in the Pharmaceuticals & Biotechnology sector or broader market.

Sector and Market Context

Piramal Pharma operates within the Pharmaceuticals & Biotechnology sector, a space often characterised by innovation-driven growth and regulatory complexities. Compared to sector peers, the company’s financial and operational metrics lag behind, which is reflected in its lower Mojo Score of 30.0 and the Sell grade.

Market capitalisation remains in the smallcap category, which can entail higher volatility and risk. Investors seeking exposure to this sector might consider companies with stronger fundamentals and more attractive valuations to balance risk and reward effectively.

Summary of Key Metrics as of 02 October 2026

The latest data shows the following key metrics for Piramal Pharma Ltd:

• Mojo Score: 30.0 (Sell Grade)
• Operating Profit CAGR (5 years): -9.27%
• Debt to EBITDA Ratio: 6.16 times
• Return on Equity (avg): 0.58%
• Profit Before Tax excluding Other Income (Q): -₹96.87 crores (-100.5%)
• ROCE (Half Year): 2.61%
• Debt-Equity Ratio (Half Year): 0.70 times
• Enterprise Value to Capital Employed: 2.5
• Stock Returns: 1D: -3.22%, 1W: -4.08%, 1M: -6.36%, 3M: +18.45%, 6M: +39.86%, YTD: +15.87%, 1Y: +0.18%

These figures collectively explain the rationale behind the current Sell rating and highlight the challenges the company faces in delivering sustainable shareholder value.

Investor Takeaway

For investors, the current Sell rating signals a need for prudence. While the stock has shown some short-term price resilience, the underlying fundamentals and financial health raise concerns about the sustainability of gains. Monitoring future quarterly results and any strategic initiatives by management will be crucial to reassessing the stock’s outlook.

Investors seeking exposure to the pharmaceutical sector should consider companies with stronger financial trends and more attractive valuations to optimise portfolio performance and risk management.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today